Genmab — April 2017

[bibob]

Skriv dagen i kalenderen.. det bliver spændende.

[E_L]

Haven't heard anything about the 2nd NICE Committee meeting on Apr 20, thought those meetings were public. Looks like we have to wait until July for the small chance they will surprise us with a UK approval. https://www.nice.org.uk/guidance/indevelopment/gid-ta10076

[bibob]

Er der nogen der har adgang og kan se om Dara blev godkendt af EMA. ? http://medwatch.dk/secure/Medicinal___Biotek/article9526585.ece?utm_campaign=Middag&utm_content=2017-04-24 12%3A16%3A13&utm_medium=top&utm_source=Feed

[E_L]

We are waiting for the European Comission now, who should approve based on the positive recommendation EMA already gave -if i am correc
t?

[bibob]

Yes that`s right. It should come this week . I guess Friday.

[bibob]

LUK : 1310.

[Bulder]

@ gentogen: dit link ang dara pom i går kl 10:51 skulle vist have været dette her https://www.youtube.com/watch?v=-6M0a51-xyw

[Bulder]

Men rigtigt, han er meget begejstret for dara-pom

[JKY_VH]

er du ikke lidt beskeden bibob?

[bibob]

Jo.- Det var da et elendigt bud.

[JKY_VH]

ja, nu må du stramme dig an:-)

[bibob]

Skal nok.

[gentogen]

Tak Bulder! Helt rigtigt.

[Bulder]

Og Sagar Lonial er jo ikke hvem som helst. Han har et hav af ledende tillidsposter inden for MM. FDA kan umuligt gå uden om godkendelse af dara-pom

[gentogen]

Lidt apropos: http://www.myelomabeacon.com/docs/ash2016/492.pdf

[gentogen]

Se konklusionerne!

[Thomas]

"From our data 80% of these heavily pretreated patients that were penta- refractory were alive at the 8 month follow up."

[Thomas]

"These extended survival results are surprising and suggest the benefits of DARA and POM last beyond progression clear biological rationale should be investigated."

[Thomas]

Det lyder hyggeligt nok

[Bulder]

Det mest overraskende er at de kan fremvise en ORR på 33,3% i cohort 3, hvor pts er resistente over for både dara og pom. Men kombinerer man dem, så sker der ting og sager.